BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 19896452)

  • 1. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.
    Livingston BD; Little SF; Luxembourg A; Ellefsen B; Hannaman D
    Vaccine; 2010 Jan; 28(4):1056-61. PubMed ID: 19896452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of an anthrax DNA vaccine with electroporation.
    Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
    Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
    Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein- and DNA-based anthrax toxin vaccines confer protection in guinea pigs against inhalational challenge with Bacillus cereus G9241.
    Palmer J; Bell M; Darko C; Barnewall R; Keane-Myers A
    Pathog Dis; 2014 Nov; 72(2):138-42. PubMed ID: 25044336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.
    Price BM; Liner AL; Park S; Leppla SH; Mateczun A; Galloway DR
    Infect Immun; 2001 Jul; 69(7):4509-15. PubMed ID: 11401993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague.
    Albrecht MT; Livingston BD; Pesce JT; Bell MG; Hannaman D; Keane-Myers AM
    Vaccine; 2012 Jul; 30(32):4872-83. PubMed ID: 22633906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
    Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses.
    Midha S; Bhatnagar R
    Eur J Immunol; 2009 Jan; 39(1):159-77. PubMed ID: 19130551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
    Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic immunization against anthrax.
    Galloway D; Liner A; Legutki J; Mateczun A; Barnewall R; Estep J
    Vaccine; 2004 Apr; 22(13-14):1604-8. PubMed ID: 15068841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
    Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
    Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection.
    Hepler RW; Kelly R; McNeely TB; Fan H; Losada MC; George HA; Woods A; Cope LD; Bansal A; Cook JC; Zang G; Cohen SL; Wei X; Keller PM; Leffel E; Joyce JG; Pitt L; Schultz LD; Jansen KU; Kurtz M
    Vaccine; 2006 Mar; 24(10):1501-14. PubMed ID: 16271808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of anthrax vaccines using protective antigen-expressing viral replicon vectors.
    Wang HC; An HJ; Yu YZ; Xu Q
    Immunol Lett; 2015 Feb; 163(2):206-13. PubMed ID: 25102364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
    Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.
    Krishnan V; Andersen BH; Shoemaker C; Sivko GS; Tordoff KP; Stark GV; Zhang J; Feng T; Duchars M; Roberts MS
    Clin Vaccine Immunol; 2015 Apr; 22(4):430-9. PubMed ID: 25673303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
    Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
    Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for improved anthrax vaccines.
    Brey RN
    Adv Drug Deliv Rev; 2005 Jun; 57(9):1266-92. PubMed ID: 15935874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
    Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
    Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.